Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We focus on the new prognostic and predictive factors CD44, PDL1, and ATG7 in our study of surgical samples of patients with laryngeal squamous cell carcinoma (LSCC) using tissue microarray (TMA). Thirty-nine previously untreated patients affected by laryngeal carcinoma who then underwent surgical treatment were considered in this retrospective study. All surgical specimens were sampled, embedded in paraffin blocks, and stained with hematoxylin and eosin. A representative sample of the tumor was chosen and transferred into a new block of paraffin, the recipient block, to perform immunohistochemical analysis with the primary antibodies anti-CD44, PD-L1, and ATG7. At follow-up, 5-year disease-free survival (DFS) for negative and positive tumors was determined as 85.71% and 36% for CD44, 60% and 33.33% for PDL1, and 58.06% and 37.50% for ATG7, respectively. Multivariate analysis revealed that CD44 expression is an independent predictive factor of low-grade tumors ( = 0.008), lymph node metastasis at the time of diagnosis, and AGT7 negativity. Thus, CD44 expression is a potential marker for more aggressive forms of laryngeal cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177409PMC
http://dx.doi.org/10.3390/cancers15092461DOI Listing

Publication Analysis

Top Keywords

cd44 pdl1
8
pdl1 atg7
8
laryngeal squamous
8
squamous cell
8
tissue microarray
8
microarray tma
8
prognostic predictive
8
study surgical
8
patients laryngeal
8
cd44 expression
8

Similar Publications

Background: Immune checkpoint inhibitors (ICIs) have become an integral part of cancer therapy, but only a minority of patients experience durable responsiveness. Response rates vary greatly and are often unpredictable, highlighting the urgent need for predictive biomarkers to guide treatment decisions.

Methods: We investigated immune- and tumor-specific expression and secretion profiles in peripheral blood and tumor samples derived from patients with head and neck squamous cell carcinoma (HNSCC).

View Article and Find Full Text PDF

MIL-100(Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway.

Acta Biomater

August 2025

Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, China; State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China; Innovation Laboratory for Sciences and Technologies

Colorectal cancer (CRC) remains a major global health burden as the third most commonly diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. While combination chemotherapy and immune agonists hold potential to overcome tumor heterogeneity through multi-pathway modulation, their therapeutic efficacy remains limited by off-target drug distribution and immunosuppressive tumor microenvironment (TME). To address this, we developed a tumor-targeted chemo-immunotherapy platform by encapsulating irinotecan (CPT-11) and resiquimod (R848) in hyaluronic acid (HA) coated MIL-100(Fe) metal-organic frameworks (CRMH NPs), enabling CD44-mediated delivery and synergistic anti-tumor responses.

View Article and Find Full Text PDF

Background/objectives: Brain metastasis (BM) is a common and often early manifestation in lung adenocarcinoma (LUAD), yet its tumor microenvironment remains poorly defined at the time of initial diagnosis. This study aims to characterize early immune microenvironmental alterations in synchronous BM using spatial proteomic profiling.

Methods: We performed digital spatial proteomic profiling using the NanoString GeoMx platform on formalin-fixed paraffin-embedded tissues from five treatment-naïve LUAD patients in whom BM was the initial presenting lesion.

View Article and Find Full Text PDF

Enhancing chemo-immunotherapy in triple-negative breast cancer: Co-delivery of doxorubicin and berberine using nanoparticles to downregulate PD-L1 and eliminate cancer stem cells.

Int J Pharm

February 2025

Department of Pharmacy, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong, China. Electronic address:

Doxorubicin (DOX), a prominent chemotherapeutic agent for triple-negative breast cancer, can induce immunogenic cell death (ICD), while simultaneous enriching cancer stem cells (CSCs) and enhancing PD-L1 expression, leading to treatment resistance and tumor recurrence. Herein, we propose an innovative nanoparticle delivery system co-encapsulating DOX and berberine (BER), a natural alkaloid eliminating CSCs and downregulating PD-L1, to enhance chemo-immunotherapy effectiveness. In this study, a modified solvent-dialysis approach was used to encapsulate DOX and BER with hyaluronic acid (HA) and chitosan (CS).

View Article and Find Full Text PDF

In humans and cats, pancreatic carcinoma (PC) arising from the exocrine pancreas is considered an aggressive cancer associated with a poor prognosis due to its high metastatic rate. The aim of this retrospective multi-institutional study was to investigate tissue expression of biomarkers of tumour invasiveness, metastasis and immune escape in cats with PC. A secondary aim was to correlate the overall immunohistochemical scores (OISs) with histological characteristics, presence of metastasis and survival.

View Article and Find Full Text PDF